Month: March 2020

Allocation of warrants to management in FirstFarms A/S

Written by Customer Service on March 30, 2020. Posted in Public Companies.

The Board of Directors in FirstFarms A/S has today based on authorisation in the company’s Articles of Association section 5.2.A and section 5.2.B decided to issue 40,000 warrants, which each gives right to subscribe one share of nominal DKK 10 in the company. Thus, the issued warrants give right to subscribe total up to nominal DKK 400,000 shares in the company. The Board of Directors has at the same time made decision about the related capital increase.The issued warrants are allocated cost-free to the company’s CEO.The utilisation price of the allocated warrants is DKK 51,85 per share of nominal DKK 10 with a premium of 2 % p.a. calculated as from today and till notice is given about utilisation.The allocated warrants can be utilised in a period of 4 weeks from the company’s publication of the interim financial report for the period...

Tildeling af warrants til direktion i FirstFarms A/S

Written by Customer Service on March 30, 2020. Posted in Public Companies.

Bestyrelsen i FirstFarms A/S har i dag på baggrund af bemyndigelse i selskabets vedtægter § 5.2.A og § 5.2.B besluttet at udstede 40.000 stk. warrants, der hver giver ret til at tegne én aktie á nominelt 10 kr. i selskabet. De udstedte warrants giver således ret til samlet at tegne indtil nominelt 400.000 kr. aktier i selskabet. Bestyrelsen har samtidig truffet beslutning om den dertil hørende kapitalforhøjelse.De udstedte warrants er tildelt vederlagsfrit til selskabets direktør.Udnyttelseskursen for de tildelte warrants er kr. 51,85 pr. aktie á nominelt kr. 10 med et tillæg på 2 % p.a. regnet fra dags dato og til der gives meddelelse om udnyttelse.De tildelte warrants kan udnyttes i en periode på 4 uger regnet fra selskabets offentliggørelse af delårsrapporten for perioden 1. januar 2024 – 31. marts 2024.Såfremt direktøren fratræder...

Eve & Co Announces Management Change

Written by Customer Service on March 30, 2020. Posted in Public Companies.

STRATHROY, Ontario, March 30, 2020 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) today announces that Landon Roedding has tendered his resignation as the Company’s Chief Financial Officer.The Eve & Co Board of Directors would like to thank Mr. Roedding for his tireless and invaluable contributions to the Company as the CFO since October 2018. His demonstrated financial acumen and senior executive experience have been critical during this time.The Board has appointed Rory Taylor as Interim Chief Financial Officer, while the Board commences a search for a permanent successor to Mr. Roedding. Mr. Taylor previously served as the Company’s Controller and has over 10 years of public company experience in senior financial roles for various international mining companies.Mr....

Medtronic Shares Ventilation Design Specifications to Accelerate Efforts to Increase Global Ventilator Production

Written by Customer Service on March 30, 2020. Posted in Public Companies.

DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it is publicly sharing the design specifications for the Puritan Bennett™ 560 (PB 560) to enable participants across industries to evaluate options for rapid ventilator manufacturing to help doctors and patients dealing with COVID-19. This decision is consistent with the recent FDA Guidance and in accordance with the public health and medical response of governmental agencies globally.

Tauriga Sciences, Inc. Reports Continued Surge in its E-Commerce Business Segment

Written by Customer Service on March 30, 2020. Posted in Public Companies.

On Sunday March 29, 2020 – The Company Set New Daily Records for: Revenue Generated and Number of Individual TransactionsNEW YORK, NY, March 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today confirmed that its E-Commerce business segment is continuing to show strength and rapid growth. On Sunday March 29, 2020, the Company set new daily records for both its E-Commerce revenue generated as well as number of individual transactions. For the first time, the Company generated in excess of $4,000 in daily E-Commerce revenue. The E-Commerce business...

I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea

Written by Customer Service on March 30, 2020. Posted in Public Companies.

-The clinical study will explore the potential of TJM2, an anti-GM-CSF monoclonal antibody, to treat cytokine release syndrome in severe and critically ill patients with coronavirus disease-Submission follows the announcement of plans to develop TJM2 in the U.S. for the same indicationSHANGHAI, China, and ROCKVILLE, MD., March 30, 2020 (GLOBE NEWSWIRE) — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced that it has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety (MFDS), to evaluate the safety and efficacy of TJM2 in treating...

FIRST QUANTUM PROVIDES NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND FILING OF ANNUAL DISCLOSURE AND REGULATORY DOCUMENTS

Written by Customer Service on March 30, 2020. Posted in Public Companies.

TORONTO, March 30, 2020 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“FQM” or the “Company”) (TSX: FM) provides notice that the Annual and Special Meeting of Shareholders will take place on May 7 2020, at 09:30 am EDT online through the Company’s website (www.first-quantum.com) or directly at https://web.lumiagm.com/286180665 and at Vantage Venues, 150 King St. West, 27th Floor, Toronto, ON, M5H 1J9, Canada.ANNUAL DISCLOSURE DOCUMENTSThe Company’s 2019 Annual Report and the 2020 Notice & Access Document, Combined Notice and Management Information Circular, Proxy Form, Financial Statements Request Form and Voting Instruction Form are now available online at https://www.first-quantum.com/English/investors/investor-briefcase/default.aspx.UPDATED NATIONAL INSTRUMENT 43-101 TECHNICAL REPORT FOR SENTINEL AND ENTERPRISEIn addition,...

TRxADE GROUP, INC. REPORTS 2019 RESULTS

Written by Customer Service on March 30, 2020. Posted in Public Companies.

Delivered 2019 annual revenues of $7.43 Million (94.1% increase)Total Adjusted EBITDA of $852,647 (249% increase)Launched next generation of Telehealth Platform ( www.Bonumhealth.com ) Launched Drug delivery platform using our network of pharmacies (www.delivmeds.com)Listed on the NASDAQ, symbol: MEDSReceived net proceeds of approximately $5.3 million through a public stock offeringTAMPA, FL, March 30, 2020 (GLOBE NEWSWIRE) — Trxade Group, Inc., (Nasdaq: MEDS) (“Trxade Group” or the “Company”), an integrated telehealth, drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, announced annual results for the year ended December 31, 2019.2019 Annual Results Summary:Revenues from continuing operations was $7.43 million compared...

PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights

Written by Customer Service on March 30, 2020. Posted in Earnings Releases And Operating Results.

Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of TicagrelorReceived FDA Breakthrough Therapy Designation and EMA PRIME Designation for PB2452Secured PB2452 Financing and Co-Development Collaboration with SFJ Pharmaceuticals®MALVERN, Pa. and SAN DIEGO, March 30, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2019, and provided an update on corporate activities.PB2452 Phase 3 Initiation Update: PhaseBio recently commenced its PB2452 Phase 3 trial. The pivotal Phase 3 trial of PB2452 will evaluate the reversal of the antiplatelet activity of ticagrelor...

DYNACOR ANNONCE UNE NEUVIÈME ANNÉE CONSÉCUTIVE DE PROFITS AVEC UN RESULTAT NET DE 5,2 M$ US EN 2019 EN AUGMENTATION DE 8%

Written by Customer Service on March 30, 2020. Posted in Earnings Releases And Operating Results.

MONTRÉAL, 30 mars 2020 (GLOBE NEWSWIRE) — Mines d’or Dynacor Inc. (TSX: DNG) (OTC: DNGDF) (Dynacor ou la Société) a publié ses états financiers consolidés audités et son rapport de gestion pour l’exercice clos le 31 décembre 2019.Ces documents ont été déposés électroniquement sur SEDAR au www.sedar.com et sont accessibles sur le site Web de la Société au www.dynacor.com. (Tous les montants dans ce communiqué sont en million de dollars américains, à moins d’indication contraire. Le résultat par action et les flux monétaires par action sont en dollars américains. Les montants de % de variation ont été calculés à partir des chiffres arrondis.)Les résultats financiers 2019 reflètent la neuvième année consécutive de profits pour la Société qui a enregistré un résultat net de 5,2 M$ (0,13 $ OU 0,17 $ CA par action) en augmentation de...

Month: March 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals